{"id":16285,"date":"2026-03-24T10:17:39","date_gmt":"2026-03-24T04:47:39","guid":{"rendered":"https:\/\/www.torusdigital.com\/toruscope\/?p=16285"},"modified":"2026-03-24T10:17:39","modified_gmt":"2026-03-24T04:47:39","slug":"sai-parenteral-ipo-opens-key-details-investors-shouldnt-miss","status":"publish","type":"post","link":"https:\/\/www.torusdigital.com\/toruscope\/news\/sai-parenteral-ipo-opens-key-details-investors-shouldnt-miss\/","title":{"rendered":"Sai Parenteral IPO Opens: Key Details Investors Shouldn\u2019t Miss"},"content":{"rendered":"

[vc_section el_id=”blog-inner-layout”][vc_row overlay_dotted=””][vc_column el_class=”blog_primary”][vc_row_inner][vc_column_inner][vc_column_text css=””]<\/p>\n

\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n

India\u2019s IPO market continues to remain active, with companies across sectors such as pharmaceuticals<\/a>, infrastructure<\/a>, and manufacturing tapping into public markets to fuel growth. The pharmaceutical sector, in particular, has been witnessing strong momentum driven by increasing healthcare<\/a> demand, expansion into global markets, and rising focus on research and development. Investors are increasingly looking at pharma companies with diversified product portfolios and export capabilities as long term growth opportunities.<\/p>\n

Against this backdrop, Sai Parenteral\u2019s Limited is set to open its IPO on March 24, 2026. Here is a detailed insight into Sai Parenteral\u2019s Limited, its IPO, and the industry outlook.<\/p>\n

\n

About Sai Parenteral\u2019s Ltd.<\/h1>\n

Incorporated in 2001, Sai Parenteral\u2019s Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing. The company operates across two key segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) services, catering to both domestic and international markets.<\/p>\n

The company offers a wide range of pharmaceutical products across multiple therapeutic areas, including cardiovascular, neuropsychiatry, anti diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements, analgesics, and dermatology. Its product portfolio spans various dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.<\/p>\n

Sai Parenteral\u2019s serves a broad customer base, including central and state government agencies, pharmaceutical companies, hospitals, and distribution networks across India. The company expanded into exports in FY 2023 and now supplies to regulated and semi regulated markets including Australia, New Zealand, Southeast Asia, the Middle East, and Africa.<\/p>\n

The company operates five manufacturing facilities in India, primarily located in Hyderabad, Telangana, along with a facility in Ongole, Andhra Pradesh through its subsidiary. These facilities are accredited with certifications such as WHO GMP, TGA Australia, and PIC S, ensuring high quality manufacturing standards.<\/p>\n

As of December 31, 2025, the company had 298 full time employees.<\/p>\n

\n

Sai Parenteral\u2019s Ltd. IPO Details<\/h1>\n

Sai Parenteral\u2019s IPO is a book building issue of \u20b9408.79 crore<\/strong>. The issue is a combination of:<\/p>\n

\u2022 Fresh issue of 0.73 crore shares aggregating to \u20b9285 crore
\u2022 Offer for sale of 0.32 crore shares aggregating to \u20b9123.79 crore<\/p>\n

The proceeds from the fresh issue will be utilised towards capacity expansion, research and development, debt repayment, working capital requirements, and investment in its overseas subsidiary.<\/p>\n

\n

Important IPO Timeline<\/h1>\n
\n
\n\n\n\n\n\n\n\n\n\n\n
Event<\/th>\nDate<\/th>\n<\/tr>\n<\/thead>\n
IPO Open Date<\/td>\nMarch 24, 2026<\/td>\n<\/tr>\n
IPO Close Date<\/td>\nMarch 27, 2026<\/td>\n<\/tr>\n
Allotment Date (Tentative)<\/td>\nMarch 30, 2026<\/td>\n<\/tr>\n
Initiation of Refunds<\/td>\nApril 1, 2026<\/td>\n<\/tr>\n
Credit of Shares to Demat<\/td>\nApril 1, 2026<\/td>\n<\/tr>\n
Listing Date (Tentative)<\/td>\nApril 2, 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
\n

Key IPO Details<\/h1>\n

Here is the table on the Sai Parenteral\u2019s IPO Review:<\/p>\n

\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Particulars<\/th>\nDetails<\/th>\n<\/tr>\n<\/thead>\n
Face Value<\/td>\n\u20b95 per share<\/td>\n<\/tr>\n
Issue Price Band<\/td>\n\u20b9372 to \u20b9392 per share<\/td>\n<\/tr>\n
Lot Size<\/td>\n38 Shares<\/td>\n<\/tr>\n
Total Issue Size<\/td>\n1,04,28,288 shares (aggregating up to \u20b9409 Cr)<\/td>\n<\/tr>\n
Fresh Issue<\/td>\n72,70,408 shares (\u20b9285 Cr)<\/td>\n<\/tr>\n
Offer for Sale<\/td>\n31,57,880 shares (\u20b9124 Cr)<\/td>\n<\/tr>\n
Issue Type<\/td>\nBookbuilding IPO<\/td>\n<\/tr>\n
Listing at<\/td>\nBSE, NSE<\/td>\n<\/tr>\n
Market Cap (Pre IPO)<\/td>\n\u20b91,731.83 Cr<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
\n

Lot Size of Sai Parenteral\u2019s IPO<\/h1>\n

Here is the table of lot sizes for each category of investors:<\/p>\n

\n
\n\n\n\n\n\n\n\n\n\n
Application<\/th>\nLots<\/th>\nShares<\/th>\nAmount<\/th>\n<\/tr>\n<\/thead>\n
Retail (Min)<\/td>\n1<\/td>\n38<\/td>\n\u20b914,896<\/td>\n<\/tr>\n
Retail (Max)<\/td>\n13<\/td>\n494<\/td>\n\u20b91,93,648<\/td>\n<\/tr>\n
S HNI (Min)<\/td>\n14<\/td>\n532<\/td>\n\u20b92,08,544<\/td>\n<\/tr>\n
S HNI (Max)<\/td>\n67<\/td>\n2,546<\/td>\n\u20b99,98,032<\/td>\n<\/tr>\n
B HNI (Min)<\/td>\n68<\/td>\n2,584<\/td>\n\u20b910,12,928<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
\n

Sai Parenteral\u2019s Ltd. Financials<\/h1>\n

Sai Parenteral\u2019s Limited has demonstrated steady growth in its financial performance, supported by expansion into global markets and a diversified pharmaceutical portfolio.<\/p>\n

<\/span>Key Company Financials (\u20b9 Crore)<\/span><\/h3>\n
\n
\n\n\n\n\n\n\n\n\n\n\n\n
Period Ended<\/th>\n30 Sep 2025<\/th>\n31 Mar 2025<\/th>\n31 Mar 2024<\/th>\n31 Mar 2023<\/th>\n<\/tr>\n<\/thead>\n
Assets<\/td>\n376.24<\/td>\n272.39<\/td>\n268.10<\/td>\n133.96<\/td>\n<\/tr>\n
Total Income<\/td>\n89.43<\/td>\n163.74<\/td>\n155.18<\/td>\n97.03<\/td>\n<\/tr>\n
Profit After Tax<\/td>\n7.76<\/td>\n14.43<\/td>\n8.42<\/td>\n4.38<\/td>\n<\/tr>\n
EBITDA<\/td>\n16.24<\/td>\n39.44<\/td>\n31.70<\/td>\n17.64<\/td>\n<\/tr>\n
Net Worth<\/td>\n209.37<\/td>\n95.78<\/td>\n76.40<\/td>\n31.49<\/td>\n<\/tr>\n
Reserves and Surplus<\/td>\n188.84<\/td>\n80.36<\/td>\n61.30<\/td>\n24.34<\/td>\n<\/tr>\n
Total Borrowing<\/td>\n76.07<\/td>\n93.95<\/td>\n118.79<\/td>\n68.55<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n

<\/span>Key Performance Indicators<\/span><\/h3>\n
\n
\n\n\n\n\n\n\n\n\n\n
KPI<\/th>\nSep 30, 2025<\/th>\nMar 31, 2025<\/th>\n<\/tr>\n<\/thead>\n
ROE<\/td>\n5.13%<\/td>\n16.82%<\/td>\n<\/tr>\n
ROCE<\/td>\n9.28%<\/td>\n28.92%<\/td>\n<\/tr>\n
RoNW<\/td>\n5.09%<\/td>\n15.09%<\/td>\n<\/tr>\n
PAT Margin<\/td>\n8.93%<\/td>\n8.88%<\/td>\n<\/tr>\n
EBITDA Margin<\/td>\n18.68%<\/td>\n24.18%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
\n

Sai Parenteral\u2019s Ltd.: Industry Outlook<\/h1>\n

\u2022 The global pharmaceutical market is witnessing strong growth driven by rising healthcare expenditure and increasing demand for generic medicines.<\/p>\n

\u2022 India continues to be one of the largest suppliers of generic drugs globally, supporting export led growth for pharma companies.<\/p>\n

\u2022 Increasing demand for contract development and manufacturing services is driving growth for CDMO focused companies.<\/p>\n

\u2022 Expansion into regulated markets such as Australia and Europe is opening new revenue streams for Indian pharma companies.<\/p>\n

\u2022 Growing focus on research, innovation, and compliance standards is expected to benefit companies with strong manufacturing capabilities.<\/p>\n

\n

Conclusion<\/h1>\n

Sai Parenteral\u2019s Limited presents a compelling opportunity in the pharmaceutical sector with its diversified product portfolio, strong CDMO presence, and expanding global footprint. The company\u2019s investments in manufacturing capacity, research and development, and international expansion position it well for future growth.<\/p>\n

However, investors should consider that the IPO is priced at relatively higher valuation levels, and performance will depend on execution of expansion plans and growth in export markets.<\/p>\n

Well informed investors may evaluate this opportunity carefully and consider investing with a medium to long term perspective.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/article>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/article>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/article>\n<\/div>\n

[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/2″][vc_column_text css=””][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_id=”share_rating”][vc_column_inner width=”1\/2″][vc_column_text css=””]<\/p>\n

Rate this article<\/h6>\n